To investigate the efficacy and safety of edaravone and dexborneol in the treatment of acute cerebral infarction.

A total of 120 patients with acute cerebral infarction for intravenous thrombolysis were selected, and were treated with alteplase 0.9 mg·kg^-1 for thrombolysis. Then they were divided into control group and study group (n=60 in each group). The study group received intravenous infusion of 37.5 mg of edaravone and dexborneol injection after thrombolysis, once every 12 hours, for a course of ≤14 days. The baseline data, National Institutes of Health Stroke Scale (NIHSS) scores before and after thrombolysis at 30 minutes, 24 hours and 7 days, modified Rankin Scale (mRS) scores before and after thrombolysis at 24 hours and 7 days, the levels of hypersensitive C-reactive protein (hsCRP) and interleukin-6 (IL-6) before and after thrombolysis at 7 days, and the occurrence of adverse events were observed.

After 30 minutes of thrombolysis, the NIHSS scores of the two groups were significantly reduced compared with before thrombolysis (P<0.05), and there was no significant difference between the groups (P>0.05). At 24 hours and 7 days after thrombolysis, the NIHSS and mRS scores of the two groups were significantly lower than before thrombolysis, and the study group was lower than the control group (P<0.05). The total effective rates of the study group and the control group were 80% and 63%, respectively, with significant differences between the two groups (P<0.05). At 7 days after thrombolysis, the levels of hsCRP and IL-6 in the two groups were significantly lower than those before thrombolysis (P<0.05), while the study group was significantly lower than the control group (P<0.05). During the thrombolysis process, the adverse reactions in the study group and control group were 20% and 22%, respectively, with no significant difference between the two groups (P>0.05).

The clinical efficacy of edaravone and dexborneol combined with alteplase in the treatment of acute cerebral infarction is better than that of alteplase alone, and does not increase the risk of thrombolytic therapy.